* 1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.[link](https://www.ncbi.nlm.nih.gov/pubmed/30643254)

* 2. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.[link](https://www.ncbi.nlm.nih.gov/pubmed/30664300)

* 3. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.[link](https://www.ncbi.nlm.nih.gov/pubmed/31361563) 

* 4. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.[link](https://www.ncbi.nlm.nih.gov/pubmed/31515453)

* 5. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.[link](https://www.ncbi.nlm.nih.gov/pubmed/30395155)  

* 6. Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma. [link](https://www.ncbi.nlm.nih.gov/pubmed/32158626)